Rapamycin in Healthy Adults: First PEARL Trial Results

By Longevity Lab · Published: July 29, 2026

Based on peer-reviewed research — full source list at the end of this article. This is educational information, not medical advice.

The PEARL trial, one of the first placebo-controlled studies of rapamycin in healthy adults, has finished. Low intermittent doses taken for about a year were reasonably well tolerated with no serious safety signals, and they produced only modest improvements on individual measures rather than any breakthrough rejuvenation. Researchers have studied this drug for decades as a possible geroprotector, and the question was simple but important: is it safe for healthy people to take it “for longevity,” and is there any point? The answer matters to doctors as much as to biohacking enthusiasts, because patients increasingly arrive asking about “pills for old age.”

Where rapamycin came from

Rapamycin (sirolimus) was isolated from a soil bacterium found on Easter Island (Rapa Nui), which is where the name comes from. It suppresses the cell’s growth switch, a protein called mTOR, and slowing mTOR is linked to the mechanisms of longevity. In medicine, rapamycin has long been used as an immunosuppressant, for example to prevent rejection of transplanted organs, and it also appears in some cancer treatment regimens. The mTOR pathway is one of several levers behind why bodies age at different speeds, a picture we sketch out in Longevity — the science of aging more slowly.

Animals are where rapamycin has looked most impressive. Independent laboratories found that it reliably extended the lifespan of mice, even when treatment started in old age. That is one of the most reproducible results in the biology of aging, and it is what created the interest in testing the drug in people.

What the PEARL rapamycin trial found

PEARL was a decentralized, double-blind, placebo-controlled study: participants took low intermittent doses of rapamycin or placebo for about a year. The results:

• the drug was generally well tolerated: the rate of adverse events was comparable to placebo, and no serious safety signals were identified;
• modest improvements were recorded on individual measures (for example muscle mass and self-reported well-being in some subgroups);
• breakthrough rejuvenation, or any sharp improvement in health, did not happen.

The main value of PEARL is its safety data on intermittent dosing in healthy people, not proof of a longevity benefit. The intermittent schedule exists precisely to reduce the side effects typical of rapamycin: mouth ulcers, and effects on metabolism and immunity.

Can you take rapamycin for longevity

The results are cautiously encouraging, but this is an early stage. The key points to keep in mind:

• rapamycin is a prescription immunosuppressant, not a harmless supplement;
• it carries risks: effects on immunity, on metabolism and on wound healing;
• the trial showed acceptable tolerability but did not prove life extension in humans;
• taking it on your own “for longevity” is not justified, and larger, longer studies are needed.

Science is moving in this direction. Related targets and other mTOR drugs are under study, for example for strengthening immunity in older adults. For now, though, this is an area of active research rather than a finished recommendation.

From mice to humans: where it gets stuck

Rapamycin is a showcase of how hard it is to carry geroprotectors from animals to people. In mice it extends lifespan reliably, but mice live two to three years, so a year of treatment is a noticeable share of their life. Experiments of that length are unthinkable in humans, so researchers have to lean on surrogate markers (immunity, muscle, well-being) and hope those predict what actually matters: health and lifespan — in one word, Healthspan (healthy life expectancy). Which of those markers deserves that trust is a question in its own right, and we compare the available options in Biological age tests: what to measure and how to choose a method.

The second question is dose and schedule. In transplant medicine, rapamycin is given continuously and at doses that suppress the immune system. For longevity, researchers test infrequent low doses instead, trying to catch the benefit without suppressing the body’s defenses. PEARL is part of the search for that window where an effect exists but harm does not.

What else is being studied in this direction:

• analogue drugs (rapalogs) for strengthening immunity in older adults;
• combinations with other interventions, and the best intermittent schedules;
• biomarkers that show an effect quickly, without waiting decades — in other words, a validated Biomarker of aging.

Metformin, rapamycin and the temptation to self-medicate

Rapamycin is often named in the same breath as metformin, another candidate geroprotector. They are different drugs with different targets and different risk profiles, and what they share is the cautious optimism of researchers rather than proven benefit for healthy people. Neither is approved “for longevity” today. Approaches that nudge the same nutrient-sensing machinery without a prescription, such as the eating schedules we examine in Intermittent Fasting and Aging, Minus the Hype, carry the same caveat: interesting mechanisms, thin human outcome data.

The main danger around drugs like these is the temptation to self-medicate from instructions found online. Rapamycin suppresses the immune system, and the wrong dose can turn into infections and other complications. Any conversation about it outside a medical indication is a conversation with a doctor, not a solo experiment.

Why you should not run ahead of the science:

• doses and schedules for healthy people have not been established;
• the long-term risks of taking it “for longevity” are unknown;
• the quality of grey-market drugs is not guaranteed;
• the potential harm can outweigh the hypothetical benefit.

Frequently asked questions

Source: Mannick JB, Lamming DW and PEARL trial data: rapamycin in healthy adults, 2024. PubMed →

Disclaimer. This article is for information only and does not replace medical advice. Talk to a qualified clinician before changing anything about your health.